MX2016013631A - Celulas huespedes modificadas y usos de las mismas. - Google Patents

Celulas huespedes modificadas y usos de las mismas.

Info

Publication number
MX2016013631A
MX2016013631A MX2016013631A MX2016013631A MX2016013631A MX 2016013631 A MX2016013631 A MX 2016013631A MX 2016013631 A MX2016013631 A MX 2016013631A MX 2016013631 A MX2016013631 A MX 2016013631A MX 2016013631 A MX2016013631 A MX 2016013631A
Authority
MX
Mexico
Prior art keywords
host cells
modified host
production
pseudomonas
specific
Prior art date
Application number
MX2016013631A
Other languages
English (en)
Other versions
MX378857B (es
Inventor
Kowarik Michael
J Kemmler Stefan
L Québatte Julien
Marie- Paule Simone Jeanne FERON Christiane
Original Assignee
Glycovaxyn Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glycovaxyn Ag filed Critical Glycovaxyn Ag
Publication of MX2016013631A publication Critical patent/MX2016013631A/es
Publication of MX378857B publication Critical patent/MX378857B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1048—Glycosyltransferases (2.4)
    • C12N9/1051—Hexosyltransferases (2.4.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/104—Pseudomonadales, e.g. Pseudomonas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6415—Toxins or lectins, e.g. clostridial toxins or Pseudomonas exotoxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/21—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Pseudomonadaceae (F)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/52—Genes encoding for enzymes or proenzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70—Vectors or expression systems specially adapted for E. coli
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1048—Glycosyltransferases (2.4)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y204/00—Glycosyltransferases (2.4)
    • C12Y204/01—Hexosyltransferases (2.4.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicinal Preparation (AREA)

Abstract

Se describen aquí células huéspedes modificadas útiles en la producción de bioconjugados que se pueden usar para vacunar a sujetos contra la infección con Pseudomonas. Los genomas de las células huéspedes modificadas aquí descritas comprenden genes que codifican proteínas implicadas en la glicosilación de proteínas y también genes específicos para la producción antígenos específicos de Pseudomonas.
MX2016013631A 2014-04-17 2014-10-13 Celulas huespedes modificadas y usos de las mismas. MX378857B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201461980988P 2014-04-17 2014-04-17
PCT/EP2014/071898 WO2015158403A1 (en) 2014-04-17 2014-10-13 Modified host cells and uses thereof

Publications (2)

Publication Number Publication Date
MX2016013631A true MX2016013631A (es) 2017-02-28
MX378857B MX378857B (es) 2025-03-10

Family

ID=51726491

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016013631A MX378857B (es) 2014-04-17 2014-10-13 Celulas huespedes modificadas y usos de las mismas.

Country Status (17)

Country Link
US (1) US20170035900A1 (es)
EP (2) EP3711776B1 (es)
JP (2) JP6682451B2 (es)
CN (1) CN106794237B (es)
BR (1) BR112016023688B1 (es)
CA (1) CA2945542C (es)
CY (1) CY1123403T1 (es)
DK (1) DK3131577T3 (es)
ES (2) ES2805000T3 (es)
HR (1) HRP20201021T1 (es)
HU (1) HUE049806T2 (es)
LT (1) LT3131577T (es)
MX (1) MX378857B (es)
PL (1) PL3131577T3 (es)
PT (1) PT3131577T (es)
SI (1) SI3131577T1 (es)
WO (1) WO2015158403A1 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102594707B1 (ko) 2015-07-13 2023-10-26 피벗 바이오, 인크. 식물 형질 개선을 위한 방법 및 조성물
GB201518668D0 (en) * 2015-10-21 2015-12-02 Glaxosmithkline Biolog Sa Immunogenic Comosition
CN105732818B (zh) * 2016-03-02 2019-06-07 中国人民解放军第三军医大学 一种铜绿假单胞菌重组蛋白pop及其制备方法和应用
CN111065417B (zh) * 2017-06-23 2024-04-19 美商艾芬尼维克斯公司 免疫原性组合物
MX2020004343A (es) 2017-10-25 2021-01-08 Pivot Bio Inc Métodos y composiciones para mejorar microbios modificados que fijan nitrógeno.
WO2019084342A1 (en) 2017-10-25 2019-05-02 Pivot Bio, Inc. GENETIC TARGETS FOR TARGETING NITROGEN FIXATION FOR IMPROVING PLANT CHARACTERISTICS
JP2021529522A (ja) * 2018-06-27 2021-11-04 ピボット バイオ， インコーポレイテッド 農業用微生物種の合理的改善のためのプラットフォームとしての微生物リモデリング誘導
EA202192392A1 (ru) 2019-03-18 2022-02-09 Янссен Фармасьютикалз, Инк. Способы получения биоконъюгатов полисахаридных о-антигенов e.coli, их композиции и способы их применения
WO2020191082A1 (en) 2019-03-18 2020-09-24 Janssen Pharmaceuticals, Inc. Bioconjugates of e. coli o-antigen polysaccharides, methods of production thereof, and methods of use thereof
CN115698273A (zh) * 2020-03-12 2023-02-03 马尔西博股份有限公司 包含糖工程化细菌的疫苗
PH12023550020A1 (en) 2020-09-17 2024-03-11 Janssen Pharmaceuticals Inc Multivalent vaccine compositions and uses thereof

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
PT1481057E (pt) 2002-03-07 2006-05-31 Eidgenoess Tech Hochschule Sistema e metodo para a producao de proteinas glicosiladas recombinantes num hospedeiro procariota
DK1888761T3 (da) * 2005-05-11 2010-11-01 Eth Zuerich Rekombinante N-glycosylerede proteiner fra prokaryote celler
US8063063B2 (en) 2006-03-23 2011-11-22 Novartis Ag Immunopotentiating compounds
WO2007109813A1 (en) 2006-03-23 2007-09-27 Novartis Ag Imidazoquinoxaline compounds as immunomodulators
LT2257307T (lt) * 2008-02-20 2018-08-10 Glaxosmithkline Biologicals S.A. Biokonjugatai, gauti iš rekombinantinių n-glikozilintų baltymų iš prokariotinių ląstelių
CN102724997B (zh) * 2009-11-19 2016-09-21 格林考瓦因有限公司 在原核细胞中产生免疫原性多糖的生物合成系统
JP6339366B2 (ja) * 2010-05-06 2018-06-06 グリコヴァキシン アーゲー 莢膜グラム陽性菌のバイオコンジュゲートワクチン
CA2847621A1 (en) * 2011-09-06 2013-03-14 Glycovaxyn Ag Bioconjugate vaccines made in prokaryotic cells
BR112015004817A2 (pt) * 2012-09-10 2017-07-04 Glycovaxyn Ag bioconjugados compreendendo antígenos modificados e seus usos
ES2720040T3 (es) * 2012-10-12 2019-07-17 Glaxosmithkline Biologicals Sa Procedimientos de modificación de células hospedadoras
US20150273043A1 (en) * 2012-11-07 2015-10-01 Glycovaxyn Ag Production of recombinant vaccine in e.coli by enzymatic conjugation
CA2926523C (en) * 2013-10-11 2023-09-26 Glycovaxyn Ag Methods of host cell modification

Also Published As

Publication number Publication date
EP3711776B1 (en) 2023-01-11
JP2017513480A (ja) 2017-06-01
US20170035900A1 (en) 2017-02-09
JP6682451B2 (ja) 2020-04-15
CA2945542A1 (en) 2015-10-22
WO2015158403A1 (en) 2015-10-22
CY1123403T1 (el) 2022-03-24
MX378857B (es) 2025-03-10
CN106794237A (zh) 2017-05-31
HRP20201021T1 (hr) 2020-10-16
PL3131577T3 (pl) 2020-10-19
DK3131577T3 (da) 2020-07-13
BR112016023688A2 (en) 2018-01-30
BR112016023688B1 (pt) 2024-01-09
CN106794237B (zh) 2022-04-12
EP3711776A1 (en) 2020-09-23
HUE049806T2 (hu) 2020-10-28
EP3131577B1 (en) 2020-04-22
LT3131577T (lt) 2020-07-27
EP3131577A1 (en) 2017-02-22
CA2945542C (en) 2024-03-05
ES2805000T3 (es) 2021-02-10
JP2020114232A (ja) 2020-07-30
SI3131577T1 (sl) 2020-08-31
ES2939470T3 (es) 2023-04-24
PT3131577T (pt) 2020-07-17

Similar Documents

Publication Publication Date Title
MX2016013631A (es) Celulas huespedes modificadas y usos de las mismas.
CU20200089A7 (es) Moléculas de unión contra bcma
PE20190563A1 (es) Genes de mini-distrofina optimizados y casetes de expresion y su uso
CR20170326A (es) Anticuerpos antimiostatina, polipéptidos que contienen regiones fc variantes, y métodos de uso
CL2018000432A1 (es) Vacunas terapéuticas contra el hpv18
TWD170353S (zh) 項鍊
MX2018001531A (es) Medio de cultivo celular complementado con taurina y metodos de uso.
BR112019012342A2 (pt) anticorpos il-11
EA201792613A1 (ru) Модуляторы cot и способы их применения
GT201600185A (es) Moléculas de anticuerpo que se unen a lag-3 y usos de las mismas
CY1122214T1 (el) Αντισωματα ειδικα για ton fcrn
MX2017008817A (es) Composiciones y metodos para la glicosilacion de proteinas.
MX385585B (es) Anticuerpos anti-c10orf54 y usos de los mismos.
AR110677A1 (es) Anticuerpos anti-c1s y métodos para usarlos
MX375524B (es) Anticuerpos anti-axl.
MX2016002166A (es) Anticuerpos.
TWD173859S (zh) 電連接器
MX386055B (es) Uso de medicamentos para disminuir la evolución de la enfermedad de parkinson.
EA201692025A1 (ru) Доставка белков, осуществляемая на основе бактерий
CR20150603A (es) Metaloproteinasa de la matriz y usos del mismo
UY36617A (es) Proteínas de fusión inmunogénicas para el tratamiento del cáncer
EA201890439A1 (ru) ИММУНООНКОЛОГИЧЕСКАЯ МЕЗОДЕРМАЛЬНАЯ КЛЕТКА-ПРЕДШЕСТВЕННИК (ioMP-КЛЕТКА)
BR112016019389A8 (pt) Vacina, e, peptídeo
TWD172410S (zh) 電連接器
MX2018007298A (es) Variantes con mejores propiedades de polipéptidos de fusión relacionados con omega-hidroxilasa.